Study Suggests Smokers Switching to E-cigarettes Reduce Heart Disease Risk

Dec.04.2022
Study Suggests Smokers Switching to E-cigarettes Reduce Heart Disease Risk
A new study published in Circulation found that switching to e-cigarettes can lower the risk of heart disease by 34%.

A recent study published in Circulation suggests that switching to e-cigarettes can reduce the risk of developing heart disease by 34% among smokers.


A foreign research team has analyzed data from 32,000 adult tobacco users who participated in the nationally representative Population Assessment of Tobacco and Health (PATH) from 2013 to 2019. The researchers evaluated e-cigarette and smoking patterns and compared them to disease reports and heart disease incidence, including stroke, heart attacks, and heart failure.


According to the data, smokers have a 1.8 times higher risk of developing heart disease compared to non-smokers, while there is no statistically significant difference in the risk for heart disease between e-cigarette users and non-users. The study concludes that there is a significant link between smoking and heart disease, but no significant link between e-cigarettes and heart disease.


On the other hand, a recent study entitled "Tobacco Use Disorders and Cardiovascular Health" found that the use of combustible tobacco products, smokeless tobacco, and nicotine-containing electronic cigarettes all increase the incidence of acute and chronic cardiovascular diseases. The researchers also added that these harmful effects can be relatively quickly reduced after quitting smoking.


As a result, the research team recommends more traditional methods for quitting smoking, such as providing medication treatment, emphasizing counseling for rapidly reducing risk after quitting, and appropriate follow-up.


A study utilizing data collected from 175,000 individuals who participated in the annual national health interview survey between 2014 and 2019 has found that daily use of e-cigarettes is only associated with higher rates of heart attacks among those who also regularly smoke traditional cigarettes. Additionally, no evidence was found to suggest that individuals who exclusively use e-cigarettes and have never smoked traditional cigarettes are at risk for heart attacks.


2FIRSTS will continue to report on this issue, with further updates available on the '2FIRSTS APP'. Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Azerbaijan Parliament Passes E-cigarette Ban Bill in First Reading
Azerbaijan Parliament Passes E-cigarette Ban Bill in First Reading
Azerbaijan’s Milli Majlis has approved, in its first reading, a bill that would ban the import, export, production, storage, wholesale and retail sale, and use of electronic cigarettes and their components. The bill amends the Law on Tobacco and Tobacco Products, classifying nicotine-containing e-cigarettes as tobacco products while explicitly excluding heated tobacco products. If adopted, the law would take effect on February 1, 2026.
Dec.22 by 2FIRSTS.ai
British American Tobacco’s Irish unit says VELO pouch sales hit 29m, net revenue climbs to €33.75m
British American Tobacco’s Irish unit says VELO pouch sales hit 29m, net revenue climbs to €33.75m
British American Tobacco’s Irish subsidiary PJ Carroll & Co Ltd reported that sales of its Velo nicotine pouches nearly quintupled in 2024 to 29 million units, driving an 11% year-on-year increase in net revenue to €33.75 million. However, amid a heavy tax burden and declining traditional cigarette volumes, the company’s pre-tax profit fell 8% to €5.69 million.
Dec.01 by 2FIRSTS.ai
Special Report|With Charlie’s US Line Online, the US-Filled Vape Supply Chain Model Enters a New Phase
Special Report|With Charlie’s US Line Online, the US-Filled Vape Supply Chain Model Enters a New Phase
Charlie’s Holdings has activated its first US-based manufacturing and filling line, enabling the company’s Pachamama 25K vape series to meet Texas’ new domestic manufacturing requirements. As state-level rules tighten, the move signals a broader industry shift toward US-filled supply chains and marks an inflection point for brands historically reliant on China-based prefilled production.
Industry Insight
Dec.02
Liverpool City Region Considers Healthier Advertising Rules for Trains, Ferries and Buses — Vapes Included
Liverpool City Region Considers Healthier Advertising Rules for Trains, Ferries and Buses — Vapes Included
The Liverpool City Region is considering a region-wide clampdown on advertising for junk food, sugary drinks and vapes on publicly owned infrastructure. The move is framed as part of a broader push to promote healthier lifestyles and tackle deep-rooted health inequalities, with a particular focus on reducing children’s exposure to harmful marketing in public spaces. The plan is set to go before the Combined Authority on Friday.
Jan.23 by 2FIRSTS.ai
2Firsts’ Nine Global Turning Points: How 2025 Reshaped the Nicotine Industry
2Firsts’ Nine Global Turning Points: How 2025 Reshaped the Nicotine Industry
In 2025, the global nicotine industry reached a critical turning point. Regulatory realignment, category shifts, capital repositioning and technological intervention unfolded in parallel, loosening old structures while new ones took shape. 2Firsts reviews nine pivotal events that reshaped the industry’s trajectory.
Jan.14
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.
Regulations
Dec.20 by 2Firsts Perspectives